Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting

Abstract Aims Sacubitril/Valsartan (Sac/Val) was proven more effective than enalapril for symptomatic patients with heart failure (HF) with reduced ejection fraction (HFrEF). This study aimed to investigate eligibility, titration, and tolerability for Sac/Val in a real‐world clinical setting. Method...

Full description

Bibliographic Details
Main Authors: Charlotte Nordberg Backelin, Michael Fu, Charlotta Ljungman
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:ESC Heart Failure
Subjects:
Chronic heart failure
Eligibility
HFrEF
Pharmacological Treatment
Sacubitril–Valsartan
Tolerability
Online Access:https://doi.org/10.1002/ehf2.12644

Internet

https://doi.org/10.1002/ehf2.12644

Similar Items